Cabaletta Bio Highlights Rese-cel Progress at ACR Convergence 2025
Cabaletta Bio, Inc. (NASDAQ: CABA), a leading biotechnology company focused on innovative cell therapies for autoimmune diseases, has presented promising clinical data for its investigational treatment, rese-cel (resecabtagene autoleucel), at the ACR Convergence 2025 conference. With multiple oral and poster presentations, these updates underline the potential of rese-cel in addressing complicated autoimmune disorders.
Positive Outcomes in Myositis Trials
Key Developments
In the Phase 1/2 DM/ASyS cohort, every myositis patient who met significant registrational criteria saw major improvements without the use of immunomodulators. This marks a remarkable achievement for patients undergoing treatment for dermatomyositis and antisynthetase syndrome. Cabaletta aims to initiate a myositis registrational trial this quarter that seeks to enroll 14 patients and evaluate the effectiveness of rese-cel over a 16-week period.
Clinical Response Encouragement
Results have shown that in a cohort of systemic sclerosis patients, all participants exhibited significant improvements without the use of immunomodulators or steroids. This clinical response is crucial as it hints at rese-cel’s ability to reset the immune responses, providing hope for systemic sclerosis patients.
Enhancements in Lupus Treatment Strategies
RESET-SLE Trial Expansion
Cabaletta has expanded the RESET-SLE trial, responding to favorable clinical feedback. So far, seven out of eight lupus patients have exhibited significant clinical responses. With plans to integrate a no preconditioning cohort, the company anticipates the release of initial data in 2026. This expansion allows for inclusion of lupus patients who request therapies without preconditioning, especially important for women of child-bearing potential.
Trial Statistics and Inclusion
As of late October 2025, 76 patients had been enrolled across 77 trial sites worldwide. Cabaletta’s strategic approach to expanding its trials demonstrates a commitment to ensuring that more patients have access to promising therapeutic options.
Cabaletta’s Comprehensive Clinical Development Strategy
Innovative Research Approach
Rese-cel is engineered as an autologous CAR T-cell therapy aimed at treating autoimmune diseases by targeting CD19-positive cells. Administered as a weight-based infusion, rese-cel seeks to provide patients with a meaningful reset of their immune systems, ideally resulting in durable clinical responses and alleviating the need for ongoing treatment.
About the Company
Cabaletta Bio (NASDAQ: CABA) is focused on advancing innovative targeted cell therapies for autoimmune diseases. The company operates using its CABA™ platform, which ensures the development of engineered T-cell therapies that hold potential for deep and lasting impacts on patient health across various autoimmune diseases in rheumatology and other areas. Headquartered in Philadelphia, Cabaletta is positioned at the forefront of biotech innovation, as they work towards transformative solutions for patients.
Frequently Asked Questions
What is rese-cel?
Rese-cel is an investigational autologous CAR T-cell therapy designed to treat autoimmune diseases by targeting specific immune cells.
What clinical trials is Cabaletta currently running?
Cabaletta is conducting trials for myositis, systemic sclerosis, and lupus through their RESET program.
What were the outcomes for lupus patients in the recent trials?
In recent trials, seven of eight lupus patients showed significant clinical improvements, prompting the expansion of the RESET-SLE trial.
How does rese-cel differ from traditional treatments?
Rese-cel aims to reset the immune system without the need for chronic therapies, offering a new approach to treatment.
Where can I find more information about Cabaletta Bio?
More information can be found on Cabaletta Bio’s official website or through their corporate communications.
